Stock listing
NASDAQ:PROK ProKidney Corp. Stock
Home listing (NASDAQ) of ProKidney Corp.
Follow ProKidney Corp. into a list and get an email when it puts out news.
Share price · NASDAQ:PROK
$1.04 USD 0.00 (0.0%)
Close on Nov 20, 2026
- Day range
- $1.02 – $1.08 USDNov 20, 2026
- Volume
- 1.90M sharesNov 20, 2026
- Market cap
- $217.3M USDAt the close on Nov 20, 2026 · price × 208.9M shares outstanding
- 52-week range
- $0.87 – $2.65 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.22M USDMedian day 1.17M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PROK · Home | $1.04 USD | 0.00 (0.0%) | 1,900,570 | $1.03 | $1.08 | $1.023 | $1.04 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PROK · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.04 | 0.00 | 0.0% | $1.03 | $1.08 | $1.023 | 1,900,570 | |
| $1.04 | -0.06 | -5.5% | $1.09 | $1.10 | $1.04 | 1,796,932 | |
| $1.10 | +0.06 | +5.8% | $1.06 | $1.12 | $1.035 | 1,136,363 | |
| $1.04 | -0.005 | -0.5% | $1.025 | $1.10 | $1.01 | 1,708,501 | |
| $1.045 | -0.105 | -9.1% | $1.16 | $1.16 | $1.02 | 1,292,085 | |
| $1.15 | +0.02 | +1.8% | $1.12 | $1.18 | $1.08 | 1,086,889 | |
| $1.13 | +0.02 | +1.8% | $1.15 | $1.18 | $1.11 | 595,566 | |
| $1.11 | -0.04 | -3.5% | $1.12 | $1.165 | $1.065 | 733,340 | |
| $1.15 | +0.01 | +0.9% | $1.14 | $1.27 | $1.10 | 1,466,045 | |
| $1.14 | +0.075 | +7.0% | $1.05 | $1.16 | $1.04 | 950,830 | |
| $1.065 | -0.055 | -4.9% | $1.11 | $1.11 | $1.00 | 1,169,583 | |
| $1.12 | +0.05 | +4.7% | $1.09 | $1.14 | $1.01 | 1,236,832 | |
| $1.07 | -0.05 | -4.5% | $1.105 | $1.13 | $1.00 | 1,544,109 | |
| $1.12 | -0.175 | -13.5% | $1.33 | $1.35 | $0.87 | 7,296,417 | |
| $1.295 | -0.175 | -11.9% | $1.41 | $1.459 | $1.29 | 1,730,407 | |
| $1.47 | -0.05 | -3.3% | $1.51 | $1.53 | $1.43 | 821,228 | |
| $1.52 | +0.005 | +0.3% | $1.47 | $1.595 | $1.46 | 1,497,812 | |
| $1.515 | +0.155 | +11.4% | $1.39 | $1.55 | $1.355 | 1,367,503 | |
| $1.36 | -0.05 | -3.5% | $1.41 | $1.435 | $1.35 | 761,674 | |
| $1.41 | -0.02 | -1.4% | $1.43 | $1.44 | $1.37 | 535,233 | |
| $1.43 | -0.01 | -0.7% | $1.42 | $1.48 | $1.415 | 584,484 | |
| $1.44 | 0.00 | 0.0% | $1.44 | $1.49 | $1.44 | 601,289 | |
| $1.44 | +0.045 | +3.2% | $1.40 | $1.51 | $1.35 | 1,489,346 | |
| $1.395 | +0.065 | +4.9% | $1.35 | $1.41 | $1.35 | 966,948 | |
| $1.33 | -0.125 | -8.6% | $1.43 | $1.474 | $1.305 | 1,669,719 | |
| $1.455 | -0.015 | -1.0% | $1.44 | $1.485 | $1.42 | 1,109,236 | |
| $1.47 | -0.10 | -6.4% | $1.54 | $1.57 | $1.41 | 2,125,778 | |
| $1.57 | -0.10 | -6.0% | $1.65 | $1.68 | $1.53 | 1,598,948 | |
| $1.67 | -0.07 | -4.0% | $1.71 | $1.74 | $1.66 | 607,842 | |
| $1.74 | +0.08 | +4.8% | $1.65 | $1.75 | $1.635 | 1,385,958 | |
| $1.66 | +0.09 | +5.7% | $1.55 | $1.67 | $1.53 | 1,133,741 | |
| $1.57 | -0.03 | -1.9% | $1.56 | $1.60 | $1.55 | 832,186 | |
| $1.60 | +0.02 | +1.3% | $1.58 | $1.61 | $1.555 | 771,314 | |
| $1.58 | -0.14 | -8.1% | $1.69 | $1.735 | $1.58 | 985,935 | |
| $1.72 | +0.01 | +0.6% | $1.72 | $1.745 | $1.66 | 1,089,631 | |
| $1.71 | +0.05 | +3.0% | $1.66 | $1.76 | $1.635 | 1,511,176 | |
| $1.66 | +0.03 | +1.8% | $1.65 | $1.675 | $1.60 | 1,196,615 | |
| $1.63 | +0.02 | +1.2% | $1.61 | $1.68 | $1.605 | 1,003,290 | |
| $1.61 | +0.01 | +0.6% | $1.58 | $1.64 | $1.54 | 1,814,558 | |
| $1.60 | -0.08 | -4.8% | $1.67 | $1.69 | $1.565 | 2,166,921 | |
| $1.68 | +0.03 | +1.8% | $1.65 | $1.689 | $1.60 | 1,726,689 | |
| $1.65 | -0.18 | -9.8% | $1.81 | $1.84 | $1.65 | 1,440,852 | |
| $1.83 | +0.055 | +3.1% | $1.78 | $1.86 | $1.772 | 588,523 | |
| $1.775 | -0.135 | -7.1% | $1.90 | $1.909 | $1.715 | 1,772,952 | |
| $1.91 | +0.11 | +6.1% | $1.79 | $1.98 | $1.79 | 9,450,911 | |
| $1.80 | -0.05 | -2.7% | $1.87 | $1.905 | $1.80 | 1,048,839 | |
| $1.85 | +0.11 | +6.3% | $1.79 | $1.86 | $1.76 | 1,813,747 | |
| $1.74 | -0.07 | -3.9% | $1.81 | $1.828 | $1.72 | 1,203,113 | |
| $1.81 | +0.01 | +0.6% | $1.80 | $1.845 | $1.79 | 952,598 | |
| $1.80 | -0.04 | -2.2% | $1.88 | $1.925 | $1.80 | 1,072,321 | |
| $1.84 | -0.01 | -0.5% | $1.82 | $1.86 | $1.75 | 2,491,533 | |
| $1.85 | -0.14 | -7.0% | $1.98 | $1.985 | $1.83 | 1,409,130 | |
| $1.99 | -0.02 | -1.0% | $2.05 | $2.08 | $1.97 | 929,611 | |
| $2.01 | +0.09 | +4.7% | $1.90 | $2.09 | $1.89 | 1,225,328 | |
| $1.92 | +0.01 | +0.5% | $1.92 | $1.995 | $1.895 | 751,466 | |
| $1.91 | +0.06 | +3.2% | $1.86 | $1.95 | $1.845 | 641,215 | |
| $1.85 | -0.04 | -2.1% | $1.86 | $1.90 | $1.825 | 695,726 | |
| $1.89 | +0.06 | +3.3% | $1.83 | $1.915 | $1.781 | 1,261,895 | |
| $1.83 | +0.01 | +0.5% | $1.82 | $1.90 | $1.775 | 1,128,967 | |
| $1.82 | +0.08 | +4.6% | $1.73 | $1.835 | $1.73 | 1,157,090 | |
| $1.74 | +0.01 | +0.6% | $1.74 | $1.75 | $1.67 | 568,462 | |
| $1.73 | +0.12 | +7.5% | $1.62 | $1.76 | $1.615 | 751,688 | |
| $1.61 | 0.00 | 0.0% | $1.59 | $1.63 | $1.56 | 980,539 | |
| $1.61 | +0.19 | +13.4% | $1.43 | $1.62 | $1.43 | 1,725,776 | |
| $1.42 | -0.06 | -4.1% | $1.47 | $1.47 | $1.38 | 1,828,077 |
- Ticker
- NASDAQ:PROK
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 18, 2026
ProKidney Names Farah Ali, M.D., M.S., Chief Medical Officer
Latest deck · Nov 9, 2026
Investor Presentation (November 2026)
Investor deck · 40 slides
Latest news
ProKidney Names Farah Ali, M.D., M.S., Chief Medical Officer
Nov 18, 2026
Closed $1.04 (0.0%) on Nov 20, 2026
ProKidney Reports Third Quarter 2026 Financial Results and Business Highlights
Nov 12, 2026
Closed $1.05 (-9.1%) on Nov 13, 2026
ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update
Oct 22, 2026
Closed $1.43 (-0.7%) on Oct 22, 2026
ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026
Oct 22, 2026
Closed $1.43 (-0.7%) on Oct 22, 2026
ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights
Aug 10, 2026
Closed $1.61 (-4.7%) on Aug 11, 2026
ProKidney Appoints Kenneth Locke as Chief Technical Officer
Jun 2, 2026
Closed $1.90 (+2.7%) on Jun 2, 2026
ProKidney Reports First Quarter 2026 Financial Results and Business Highlights
May 15, 2026
Closed $1.66 (-2.9%) on May 15, 2026
ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer
Mar 25, 2026
Closed $1.83 (+2.2%) on Mar 25, 2026
ProKidney Reports Full Year 2025 Financial Results and Business Highlights
Mar 18, 2026
Closed $2.08 (-2.3%) on Mar 18, 2026
ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference
Jan 6, 2026
Closed $2.25 (+5.1%) on Jan 6, 2026
ProKidney Corp. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 11 in the last 12 months · 77 in all · newest Nov 18, 2026 · oldest 2022
- Decks
- 22 decks · latest Nov 9, 2026
Where ProKidney Corp. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PROK · Home listing · This page | NASDAQ | United States | USD |
| BMV:PROK | BMV | Mexico | MXN |
| BOATS:PROK | BOATS | United States | USD |
| BIVA:PROK | BIVA | Mexico | MXN |
Cash and shares
Nov 2026 deck · ProKidney — Investor Presentation (November 2026)
- Cash
- $142 million
Valuation
EV/sales 100× against a median of 1.3×: 5th lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $77.56M USD
- P/E
- Loss
- EV/sales
- 100×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.61
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| ProKidney Corp. · NASDAQ:PROK | US$217.3M | US$77.56M | n/a | 100× | n/a | n/a | n/a | n/a | 1.61 |
| Enanta Pharmaceuticals, Inc. · NASDAQ:ENTA | US$222.2M | US$82.43M | n/a | 1.3× | n/a | 2.8× | −108.3% | 0.7× | 1.11 |
| Clover Biopharmaceuticals Ltd. · HKEX:2197 | US$222.0M | US$206.6M | n/a | 404× | n/a | n/a | n/a | n/a | n/a |
| Northwest Biotherapeutics, Inc. · OTC:NWBO | US$220.0M | US$283.8M | n/a | 99.4× | n/a | n/a | n/a | n/a | 0.90 |
| Keros Therapeutics, Inc. · NASDAQ:KROS | US$219.7M | −US$24.67M | n/a | −0.6× | n/a | 0.8× | −152.7% | 0.1× | 1.16 |
| Immuneering Corporation · NASDAQ:IMRX | US$218.7M | US$160.5M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | 1.17 |
| Allogene Therapeutics, Inc. · NASDAQ:ALLO | US$217.5M | −US$7.44M | n/a | −1.6× | n/a | 0.6× | n/a | 0.2× | 1.93 |
| Pyxis Oncology, Inc. · NASDAQ:PYXS | US$216.5M | US$160.9M | n/a | n/a | n/a | 5.2× | n/a | 0.0× | 0.89 |
| Oryzon Genomics SA · BME:ORY | US$216.4M | US$206.7M | n/a | n/a | n/a | 1.6× | n/a | 0.1× | n/a |
| Rocket Pharmaceuticals, Inc. · NASDAQ:RCKT | US$214.1M | −US$25.02M | n/a | n/a | n/a | 0.7× | n/a | 0.1× | 1.72 |
| Orum Therapeutics, Inc. · KRX:475830 | US$212.5M | US$24.22M | 15.4× | n/a | n/a | 1.5× | n/a | 0.0× | n/a |
| Median of the others | US$218.1M | US$121.4M | 15.4× | 1.3× | 1.4× | −130.5% | 0.1× | 1.16 |
Forecasts
4 strong buy · 1 hold · 1 sell · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 7.88 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.61 · 4 analysts
- Revenue, year to Dec 2026
- 750K · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Bruce Culleton | Chief Executive Officer |
| James Coulston | Chief Financial Officer |
| Todd C. Girolamo | Chief Legal Officer and Secretary |
| Emily Butler | SVP, Biometrics |
| Jake Treese | SVP, Head of Quality |
| Joseph Stavas | SVP, Interventional Procedures |
| Carla Poulson | Chief People Officer |
| Darin J. Weber | Chief Regulatory Officer |
| Farah Ali | Chief Medical Officer |
| Greg Madison | Chief Commercial Officer |
| Ken Locke | Chief Technical Officer |
| Richard Williams | Chief Information Officer |
Board
| Director | Role |
|---|---|
| Pablo Legorreta | Chairman of the Board |
| Alan M. Lotvin | Board Member |
| Brian J. G. Pereira | Director |
| Bruce Culleton | Chief Executive Officer |
| Jennifer Fox | Board Member |
| Uma Sinha | Board Member |
| William F. Doyle | Lead Independent Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | −9.1% |
| Q2 2026 | Aug 10, 2026 · After close | −4.7% |
| Q1 2026 | May 15, 2026 | −5.8% |
| Q4 2025 | Mar 18, 2026 · After close | −6.3% |
| Q3 2025 | Nov 10, 2025 · After close | +3.7% |
| Q2 2025 | Aug 12, 2025 · After close | +5.8% |
| Q1 2025 | May 12, 2025 | +20.4% |
| Q4 2024 | Mar 17, 2025 · Before open | +5.7% |
| Q3 2024 | Nov 12, 2024 · Before open | −4.7% |
| Q2 2024 | Aug 9, 2024 · Before open | +4.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 10, 2024 · After close | +9.6% |
| Q4 2023 | Mar 22, 2024 · Before open | +2.2% |
| Q3 2023 | Nov 14, 2023 · After close | −8.6% |
| Q2 2023 | Aug 10, 2023 · After close | +1.7% |
| Q1 2023 | May 11, 2023 · After close | +1.0% |
| Q4 2022 | Mar 28, 2023 · After close | −2.6% |
| Q3 2022 | Nov 14, 2022 · Before open | −1.6% |
| Q2 2022 | Aug 12, 2022 · After close | −2.5% |
| Q1 2022 | May 16, 2022 · After close | +0.1% |
| Q4 2021 | Mar 24, 2022 · After close | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 40 slides | Nov 9, 2026 |
| Corporate Update (October 2026) | Corporate update | 55 slides | Oct 27, 2026 |
| Investor Presentation (August 2026) | Investor deck | 33 slides | August 2026 |
| Investor Presentation (May 2026) | Investor deck | 33 slides | May 15, 2026 |
| Investor Presentation (February 2026) | Investor deck | 34 slides | Feb 2, 2026 |
| Investor Presentation (January 2026) | Investor deck | 34 slides | Jan 12, 2026 |
| Investor Presentation (July 2025) | Investor deck | 19 slides | Jul 15, 2025 |
| Investor Presentation (July 2025) | Investor deck | 18 slides | Jul 8, 2025 |
| J.P. Morgan Healthcare Conference 2025 | Conference | 23 slides | January 2025 |
| Investor Presentation (September 2024) | Investor deck | 24 slides | Sep 3, 2024 |
All 22 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (June 2024) | Technical | 16 slides | Jun 14, 2024 |
| Corporate Update (June 2024) | Corporate update | 27 slides | Jun 10, 2024 |
| Technical Presentation (May 2024) | Technical | 10 slides | May 29, 2024 |
| Investor Presentation (January 2024) | Investor deck | 31 slides | Jan 26, 2024 |
| Technical Presentation (November 2023) | Technical | 29 slides | Nov 13, 2023 |
| Investor Presentation (September 2023) | Investor deck | 29 slides | Sep 11, 2023 |
| Investor Presentation (March 2023) | Investor deck | 27 slides | Mar 6, 2023 |
| J.P. Morgan Investor Conference January 2023 | Conference | 28 slides | Jan 10, 2023 |
| Investor Presentation (September 2022) | Investor deck | 37 slides | Sep 8, 2022 |
| Social Capital Suvretta Holdings Corp. III — SPAC Merger (April 2022) | SPAC merger | 56 slides | Apr 28, 2022 |
| Social Capital Suvretta Holdings Corp. III — SPAC Merger (January 2022) | SPAC merger | 19 slides | Jan 18, 2022 |
| Social Capital Suvretta Holdings Corp. III — SPAC Merger (January 2022) | SPAC merger | 70 slides | Jan 18, 2022 |
IPO
Went public as Social Capital Suvretta Holdings Corp. III, a blank check company (SPAC). Priced at US$10.00 a share on Jun 29, 2021.
- Price
- US$10.00 a share
- Shares offered
- 22,000,000 Class A ordinary shares
- Offering size
- US$220 million
- Underwriters' option
- Up to 3,300,000 more shares
- Underwriters
- Morgan Stanley, SoFi · In the order on the cover
- Shares delivered
- On or about Jul 2, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Apr 21, 2021 |
| Filed publicly | Jun 2, 2021 |
| Amended twice | Newest Jun 25, 2021 |
| Shares registered with an exchange | Jun 29, 2021 |
| Declared effective by the SEC | Jun 29, 2021 |
| Final prospectus, with the price | Jul 1, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 1, 2021 |
| S-1MEF · Registration of more shares for the same offering | Jun 30, 2021 |
| EFFECT · Notice that a registration is effective | Jun 29, 2021 |
| CERT · Exchange's certificate of listing | Jun 29, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 29, 2021 |
| CORRESP · Letter to the SEC | Jun 25, 2021 |
| CORRESP · Letter to the SEC | Jun 25, 2021 |
| CORRESP · Letter to the SEC | Jun 25, 2021 |
| S-1/A · Registration statement, amended | Jun 25, 2021 |
| UPLOAD · Letter from the SEC | Jun 15, 2021 |
All 13 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Jun 9, 2021 |
| S-1 · Registration statement | Jun 2, 2021 |
| DRS · Draft registration statement | Apr 21, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 1, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 893.0K | 76.0K | 0 | 0 | 0 | 0 | |
| Cost of revenue | 5.72M | 3.17M | 3.04M | 1.98M | |||
| Gross profit | 893.0K | 76.0K | -3.17M | -3.04M | -1.98M | ||
| Research and development | 114.1M | 127.7M | 106.7M | 82.1M | 46.3M | 21.0M | 75.2M |
| Selling, general and administrative | 51.8M | 56.1M | 44.8M | 70.9M | 8.86M | 5.67M | 4.16M |
| Operating income | -165.0M | -183.7M | -151.5M | -153.0M | -55.1M | -27.0M | -79.4M |
| Depreciation and amortization | 6.58M | 5.43M | 3.85M | 3.04M | 1.98M | 964.0K | 867.0K |
| EBITDA | -158.4M | -178.2M | -147.7M | -150.0M | -53.1M | -26.1M | -78.5M |
| Interest expense | 4.00K | 9.00K | 12.0K | 215.0K | 0 | 0 | 0 |
| Income before tax | -151.2M | -163.9M | -129.5M | -147.2M | -55.1M | -27.0M | -79.3M |
| Income tax | 414.0K | -598.0K | 6.00M | 896.0K | 38.0K | -232.0K | 361.0K |
| Net income | -69.0M | -61.2M | -35.5M | -148.1M | -55.1M | -26.7M | -79.6M |
| Earnings per share, basic | -0.52 | -0.62 | -0.57 | -0.23 | -1.73 | -0.14 | -1.01 |
| Earnings per share, diluted | -0.23 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 108.5M | 99.1M | 60.6M | 490.3M | 20.6M | 4.58M | 15.2M |
| Short-term investments | 161.5M | 259.2M | 302.3M | 0 | |||
| Receivables | 1.13M | 2.45M | 1.38M | ||||
| Current assets | 280.7M | 395.9M | 374.1M | 504.7M | 27.3M | 5.58M | 15.4M |
| Property, plant and equipment | 51.2M | 42.2M | 42.1M | 10.7M | 11.4M | 10.5M | 3.33M |
| Goodwill | 427.6K | 641.4K | |||||
| Total assets | 335.6M | 441.1M | 420.6M | 518.0M | 40.3M | 16.7M | 19.6M |
| Accounts payable | 940.0K | 3.63M | 5.10M | 3.04M | 2.83M | 781.0K | 480.0K |
| Current liabilities | 30.7M | 36.2M | 25.0M | 10.9M | 12.3M | 5.50M | 2.71M |
| Total debt | 4.04M | 3.24M | 4.41M | 2.40M | 1.33M | 1.56M | 1.11M |
| Total liabilities | 34.8M | 39.4M | 29.2M | 13.1M | 13.4M | 6.84M | 3.72M |
| Shareholders' equity | -1.01B | -995.0M | -1.10B | -1.10B | 26.9M | 9.86M | 15.9M |
| Shares outstanding | 133.9M | 97.9M | 61.7M | 61.5M | 31.9M | 186.5M | 78.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -120.1M | -126.4M | -90.1M | -77.1M | -50.3M | -25.2M | -76.8K |
| Capital spending | -15.2M | -29.5M | -34.2M | -1.85M | -5.19M | -5.46M | -1.30K |
| Free cash flow | -135.3M | -155.9M | -124.3M | -78.9M | -55.5M | -30.6M | -78.1K |
| Cash from investing | 104.0M | 20.4M | -330.0M | -1.74M | -5.19M | -5.46M | -2.97K |
| Cash from financing | 25.6M | 144.4M | -9.55M | 548.5M | 71.5M | 20.0M | 20.0K |
| Share buybacks | 0 | 0 | -9.50M | 0 | 0 | ||
| Change in cash | 9.42M | 38.5M | -429.6M | 469.7M | 16.0M | -10.6M | 15.2K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 424B5 · Prospectus | Nov 12, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Nov 12, 2026 | Other filings | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 29, 2026 | Material contract | SEC |
| S-3 · Registration statement | Oct 29, 2026 | Offer document | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Aug 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 18, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 10, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 10, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 8-K · Current report | May 29, 2026 | Meeting outcome | SEC |
| 8-K · Current report | May 15, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 30, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 17, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 17, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 17, 2026 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 18, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 18, 2026 | Results | SEC |
| 10-K · Annual report | Mar 18, 2026 | Annual report | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 12, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 2, 2026 | Current report | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Nov 19, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 10, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| DEL AM | Nov 4, 2025 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Oct 21, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 17, 2025 | Material contract | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 7, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 17, 2025 | Big-stake notice | SEC |
| 8-K12B/A | Jul 16, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 15, 2025 | Current report | SEC |
| 8-K · Current report | Jul 14, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jul 14, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jul 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 9, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 8, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 8, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jul 8, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Jul 8, 2025 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Jul 3, 2025 | Offer document | SEC |
| S-8 POS | Jul 3, 2025 | Offer document | SEC |
| S-8 POS | Jul 3, 2025 | Offer document | SEC |
| S-8 POS | Jul 3, 2025 | Offer document | SEC |
| S-8 POS | Jul 3, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Jul 3, 2025 | Offer document | SEC |
| 8-K12B | Jul 3, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 1, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 5, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 8-K · Current report | May 30, 2025 | Meeting outcome | SEC |
| 8-K · Current report | May 12, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 6, 2025 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Apr 29, 2025 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 28, 2025 | Annual report | SEC |
| 424B3 · Prospectus | Apr 28, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 24, 2025 | Other filings | SEC |
| 4 · Change in ownership | Apr 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 14, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Apr 4, 2025 | Other filings | SEC |
| S-4 · Registration statement | Mar 31, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 20, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 17, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 17, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 6, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 21, 2025 | Material contract | SEC |
| 8-K · Current report | Nov 22, 2024 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 8, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 22, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Oct 22, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Oct 18, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 19, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 3, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 9, 2024 | Results | SEC |
| 4 · Change in ownership | Aug 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 29, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Jun 25, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Jun 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jun 13, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Jun 13, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Jun 10, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 10, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 8-K · Current report | May 31, 2024 | Meeting outcome | SEC |
| 8-K · Current report | May 29, 2024 | Current report | SEC |
| 4 · Change in ownership | May 22, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 20, 2024 | Other filings | SEC |
| 4 · Change in ownership | May 16, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 10, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 10, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 26, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 23, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 18, 2024 | Other filings | SEC |
| 4 · Change in ownership | Apr 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 12, 2024 | Other filings | SEC |
| 4 · Change in ownership | Apr 2, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 2, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 1, 2024 | Other filings | SEC |
| 8-K · Current report | Mar 25, 2024 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Mar 22, 2024 | Offer document | SEC |
| 8-K · Current report | Mar 21, 2024 | Results | SEC |
| 10-K · Annual report | Mar 21, 2024 | Annual report | SEC |
| 8-K/A · Current report, amended | Mar 18, 2024 | Management or board change | SEC |
| 8-K/A · Current report, amended | Mar 18, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Mar 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 12, 2024 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 6, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 25, 2024 | Current report | SEC |
| 8-K · Current report | Jan 19, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Jan 19, 2024 | Offer document | SEC |
| 8-K/A · Current report, amended | Dec 5, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Dec 5, 2023 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Dec 1, 2023 | Other filings | SEC |
| 8-K · Current report | Nov 30, 2023 | Management or board change | SEC |
| CORRESP · Letter to the SEC | Nov 28, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 27, 2023 | Other filings | SEC |
| S-3 · Registration statement | Nov 22, 2023 | Offer document | SEC |
| 4 · Change in ownership | Nov 21, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 20, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Nov 20, 2023 | Current report | SEC |
| 4 · Change in ownership | Nov 17, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2023 | Results | SEC |
| 8-K · Current report | Nov 13, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Nov 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 3, 2023 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Nov 1, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 1, 2023 | Insider trade | SEC |
This page holds 200 of 406 filings. Open Filings
Cap table
Built by 6ix from ProKidney Corp.’s releases · as of Sep 30, 2026
- Common shares
- 208,926,941
- Fully diluted
- 208,926,941
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 208,926,941 | Sep 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 208,926,941 |
| Sep 30, 2026 | 302,371,200 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Chamath Palihapitiya Other companies: Colombier Acquisition Corp. III (Director · Since at least Feb 3, 2026); American Exceptionalism Acquisition Corp. A (Director · Since at least Sep 25, 2025); Akili Inc (Director · Jul 2, 2021 – May 2, 2023 · Past); Social Capital Suvretta Holdings Corp II (President, Director · Jul 2, 2021 – Aug 16, 2021 · Past); Social Capital Suvretta Holdings Corp IV (President, Director · Jul 2, 2021 – Aug 16, 2021 · Past); Social Capital Hedosophia Holdings Corp IV (CEO & Chairman of the Board, Director · Oct 8, 2020 – Oct 8, 2020 · Past); Social Capital Hedosophia Holdings Corp VI (CEO & Chairman of the Board, Director · Oct 8, 2020 – Oct 8, 2020 · Past); SoFi Technologies, Inc. (CEO & Chairman of the Board, Director · Oct 8, 2020 – Oct 8, 2020 · Past); Opendoor Technologies Inc (CEO & Chairman of the Board, Director · Apr 27, 2020 – Apr 27, 2020 · Past); Clover Health Investments, Corp. (CEO & Chairman of the Board, Director · Apr 21, 2020 – Apr 21, 2020 · Past); Slack Technologies Inc (Director · Jun 7, 2019 – Dec 10, 2019 · Past); Virgin Galactic Holdings, Inc. (Director · Sep 13, 2017 – Mar 18, 2021 · Past) | President, Director · Jul 2, 2021 – Aug 16, 2021 · Past |
| John M. Maraganore Other companies: City Therapeutics, Inc. (Executive Chair · Since at least Oct 19, 2026); Takeda Pharmaceutical Co. Ltd. (Director · Since at least Mar 18, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Jan 29, 2026); Rapport Therapeutics, Inc. (Venture Partner, ARCH Venture Partners and Atlas Ventures · Since at least Jun 6, 2024); Kymera Therapeutics, Inc. (Director · Since at least Jan 17, 2022); Beam Therapeutics Inc. (Board Member · Since at least Nov 5, 2021); Alnylam Pharmaceuticals, Inc. (Director · Since at least May 12, 2006); Instil Bio, Inc. (Director · Jun 11, 2025 – Nov 4, 2026 · Past); Agios Pharmaceuticals, Inc. (Director · Jul 23, 2013 – Dec 31, 2022 · Past); Bluebird bio Inc (Director · Jun 18, 2013 – Sep 14, 2017 · Past); Regulus Therapeutics Inc (Director · Oct 4, 2012 – Oct 10, 2012 · Past) | Director · Jul 11, 2022 – Jun 29, 2023 · Past |
| James Ryans Other companies: Akili Inc (Chief Financial Officer · Jun 29, 2021 – Jun 29, 2021 · Past); Social Capital Suvretta Holdings Corp II (Chief Financial Officer · Jun 29, 2021 – Jun 29, 2021 · Past); Social Capital Suvretta Holdings Corp IV (Chief Financial Officer · Jun 29, 2021 – Jun 29, 2021 · Past); Social Capital Hedosophia Holdings Corp IV (Chief Financial Officer · May 31, 2021 – May 31, 2021 · Past); Social Capital Hedosophia Holdings Corp VI (Chief Financial Officer · May 31, 2021 – May 31, 2021 · Past); Clover Health Investments, Corp. (Director · Apr 21, 2020 – Apr 21, 2020 · Past); Virgin Galactic Holdings, Inc. (Director · Feb 5, 2018 – Dec 16, 2020 · Past) | Chief Financial Officer · Jun 29, 2021 – Jun 29, 2021 · Past |
| Jennifer Fox Other companies: Zenas BioPharma, Inc. (See Remarks · Since at least Sep 12, 2024); Apogee Therapeutics, Inc. (Director · Since at least Jul 13, 2023); Nuvation Bio Inc. (Chief Financial Officer · Feb 10, 2021 – Feb 28, 2023 · Past) | Director · Since at least Jul 11, 2022 |
| Marc Semigran Other companies: Edgewise Therapeutics, Inc. (Chief Development Officer · Dec 19, 2022 – Dec 24, 2024 · Past); MyoKardia Inc (Chief Medical Officer · Dec 1, 2016 – Feb 8, 2019 · Past) | Director · Jun 29, 2021 – Jun 29, 2021 · Past |
| Mary Weger Other companies: Medidata Solutions Inc (EVP, Human Resources · Feb 23, 2017 – Feb 24, 2017 · Past); Aegerion Pharmaceuticals Inc (Chief Performance Officer · Mar 29, 2015 – Aug 4, 2015 · Past) | Chief People Officer · Dec 1, 2022 – Jan 16, 2023 · Past |
| Timothy Bertram Other companies: NexImmune, Inc. (Director · Feb 11, 2021 – Jul 5, 2023 · Past); Tengion Inc (Pres Rsrch & Dev, & Chf Sc Ofc · Apr 9, 2010 – Mar 4, 2013 · Past) | Chief Executive Officer, Director · Jul 11, 2022 – Jan 16, 2023 · Past |
| Todd C. Girolamo Other companies: Longeveron Inc. (Director · Feb 15, 2022 – Dec 21, 2022 · Past); Lisata Therapeutics, Inc. (CLO, SVP of Corp Dev · Jun 17, 2021 – Jan 13, 2022 · Past) | Chief Legal Officer and Secretary · Since at least Jul 11, 2022 |
| Brian J. G. Pereira Other companies: KalVista Pharmaceuticals, Inc. (Director · Since at least Oct 3, 2024) | Director · Since at least May 30, 2024 |
| William Doyle Other companies: NovoCure Limited (Executive Chairman · Since at least Dec 22, 2025) | Lead Independent Director · Since at least Nov 19, 2026 |
All 28 people
| Person | Seat |
|---|---|
| Alan M. Lotvin | Board Member · Since at least Nov 19, 2026 |
| Bruce Culleton | Chief Executive Officer, Director · Since at least Mar 1, 2026 |
| Carla Poulson | Chief People Officer · Since at least Nov 19, 2026 |
| Darin J. Weber | Chief Regulatory Officer · Since at least Jul 11, 2022 |
| Deepak Jain | Chief Operating Officer · Jul 11, 2022 – Jan 16, 2023 · Past |
| Emily Butler | SVP, Biometrics · Since at least Nov 5, 2026 |
| Farah Ali | Chief Medical Officer · Since at least Nov 18, 2026 |
| Greg Madison | Chief Commercial Officer · Since at least Mar 25, 2026 |
| Jake Treese | SVP, Head of Quality · Since at least Nov 19, 2026 |
| James Coulston | Chief Financial Officer · Since at least Mar 1, 2026 |
| Joseph Stavas | SVP, Interventional Procedures · Since at least Nov 19, 2026 |
| Ken Locke | Chief Technical Officer · Since at least Aug 10, 2026 |
| Libbie Parker McKenzie | Chief Medical Officer · Jul 11, 2022 – Jan 16, 2023 · Past |
| Pablo Legorreta | Chairman of the Board · Since at least Nov 19, 2026 |
| Richard Williams | Chief Information Officer · Since at least Nov 19, 2026 |
| Santos Jose Ignacio Jimenez | Director · Since at least Jul 11, 2022 |
| Ulrich Peter Alfred Ernst | EVP, Technical Operations · Mar 25, 2024 – Apr 1, 2024 · Past |
| Uma Sinha | Director · Since at least May 29, 2025 |
Log in to ask 6ix AI your own questions about ProKidney Corp.